Some price data may be temporarily unavailable.
The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
Biophytis SA operates as a clinical-stage biotechnology company. It specializes in the development of therapeutics that are aimed at slowing the degenerative processes associated with aging, including severe respiratory failure in patients suffering from COVID-19. Its products include Sarconeos (BIO101), which is used to treat sarcopenic obesity and Macuneos (BIO201), which is used to treat dry age-related macular degeneration (AMD). The company was founded by Stanislas Veillet and René Lafont on September 27, 2006 and is headquartered in Paris, France.
No news articles found for Biophytis.
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
